Stock Analysis, Dividends, Split History

ADVM / Adverum Biotechnologies, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price5.75
Volume972,700.00
Market Cap ($M)366.76
Enterprise Value ($M)211.31
Book Value ($M)233.45
Book Value / Share3.72
Price / Book1.57
NCAV ($M)224.78
NCAV / Share3.59
Price / NCAV1.63
Share Statistics
Common Shares Outstanding 62,173,278
Common Stock Shares Outstanding 49,015,339
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.31
Return on Assets (ROA)-0.24
Return on Equity (ROE)-0.26
Balance Sheet (mrq) ($M)
Assets246.59
Liabilities13.14
Quick Ration/a
Current Ratio20.92
Income Statement (mra) ($M)
License And Services Revenue1,849,000.00
Operating Income-58.85
Net Income-56.15
Earnings Per Share Basic And Diluted-1.29
Cash Flow Statement (mra) ($M)
Cash From Operations-45.42
Cash from Investing-122.20
Cash from Financing-45.42
Identifiers and Descriptors
CUSIP00773U108
Central Index Key (CIK)1501756
Related CUSIPS
05337G107 00773U958

Split History

Stock splits are used by Adverum Biotechnologies, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

How Adverum Bio Is Winning With FDA Update

13h 247wallst
Adverum Biotechnologies Inc. (NASDAQ: ADVM) shares made a handy gain on Thursday after the company announced a key update from the U.S. Food and Drug Administration (FDA). (3-0)

Why Adverum Biotechnologies (ADVM) is a Top Pick for Momentum Investors

2018-09-06 zacks
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. (7-0)

The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Cleveland-Cliffs, Callaway Golf, SkyWest and Vishay Intertechnology

2018-09-05 zacks
Chicago, IL – September 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Bristol-Myers Squibb Company (BMY - Free Report) , Cleveland-Cliffs Inc. (CLF - Free Report) , Callaway Golf Company (ELY - Free Report) , SkyWest, Inc. (9-0)

The Zacks Analyst Blog Highlights: Microsoft, Facebook, Snap and Aspen Technology

2018-09-05 zacks
Chicago, IL – September 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Microsoft (MSFT - Free Report) , Facebook (FB - Free Report) , Snap (SNAP - Free Report) and Aspen Technology, Inc. (AZPN - Free Report) . (25-0)

Zacks.com highlights: Avnet, Fortinet, Insight Enterprises, Archer Daniels Midland and AMETEK

2018-09-05 zacks
Chicago, IL – September 5, 2018 - Stocks in this week’s article include: Avnet, Inc. (AVT - Free Report) , Fortinet, Inc. (FTNT - Free Report) , Insight Enterprises, Inc. (NSIT - Free Report) , Archer Daniels Midland Co. (ADM - Free Report) and AMETEK Inc. (AME - Free Report) . (16-0)

CUSIP: 00773U108